Kyntra Bio (CH:KYNB)
:KYNB
KYNB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionInclusion of PET imaging with FG-3180 to measure the tumor marker may enable selection of patients with higher target expression, enriching for responders and improving trial efficiency.
Clinical ValidationEncouraging early-stage clinical data for FG-3246 and provocative efficacy signals versus a relevant comparator reduce development risk and support continued advancement of the lead therapy.
Regulatory Development PathwaySubmission of a pivotal trial protocol for the anemia program in lower-risk disease positions that asset for potential confirmatory development and could support regulatory progress.
Bears Say
Concentration And Execution RiskStrategic realignment concentrating resources on a single advanced prostate cancer program increases company reliance on the lead candidate and raises execution risk if development setbacks occur.
Safety And TolerabilityElevated rates of treatment discontinuation driven by peripheral neuropathy and other treatment-related adverse events create material tolerability concerns that could limit the drug's clinical impact.
Trial Comparability And Competitive LandscapeUse of a composite response measure that differs from standard metrics, combined with early-stage status in a crowded prostate cancer market, complicates cross-study comparisons and supports a cautious view until additional data are available.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Currently, no data Available
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is CHF21.65M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Aug 10, 2026 which is in 61 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on May 11, 2026. The company reported -CHF2.939 earnings per share for the quarter, missing the consensus estimate of -CHF2.622 by -CHF0.317.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -2.56.
How many shares outstanding does Kyntra Bio have?
Currently, no data Available
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of -CHF2.939 in its last earnings report, missing expectations of -CHF2.622. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in CH:KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.View all CH:KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
CHF29.10
Grace Therapeutics
―
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Options Prices
Currently, No data available
---